4BASEBIO PLC (88Q.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:88Q - GB00BMCLYF79 - Common Stock
88Q.DE Key Statistics, Chart & Performance
The current stock price of 88Q.DE is 6.95 EUR. In the past month the price decreased by -32.99%. In the past year, price decreased by -61.54%.
88Q.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 67.86 | 44.21B | ||
| ARGX.BR | ARGENX SE | 64.84 | 42.24B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.25B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.05B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.03B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.83B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 831.23M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| IVA.PA | INVENTIVA SA | N/A | 748.79M | ||
| PHIL.MI | PHILOGEN SPA | 19.82 | 660.82M |
Related stock screener links
About 88Q.DE
Company Profile
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Company Info
4BASEBIO PLC
25 Norman Way, Over
CAMBRIDGE GB
Employees: 0
Phone: 441223967943
4BASEBIO PLC / 88Q.DE FAQ
Can you describe the business of 4BASEBIO PLC?
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Can you provide the latest stock price for 4BASEBIO PLC?
The current stock price of 88Q.DE is 6.95 EUR. The price decreased by -0.71% in the last trading session.
Does 4BASEBIO PLC pay dividends?
88Q.DE does not pay a dividend.
How is the ChartMill rating for 4BASEBIO PLC?
88Q.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy 88Q stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 88Q.DE.
Who owns 4BASEBIO PLC?
You can find the ownership structure of 4BASEBIO PLC (88Q.DE) on the Ownership tab.
88Q.DE Technical Analysis
88Q.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE. The financial health of 88Q.DE is average, but there are quite some concerns on its profitability.
88Q.DE Financial Highlights
Over the last trailing twelve months 88Q.DE reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS decreased by -26.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.08% | ||
| ROE | -75.9% | ||
| Debt/Equity | 0.81 |
88Q.DE Forecast & Estimates
9 analysts have analysed 88Q.DE and the average price target is 20.21 EUR. This implies a price increase of 190.81% is expected in the next year compared to the current price of 6.95.
For the next year, analysts expect an EPS growth of -34.32% and a revenue growth 50% for 88Q.DE